Achillion To Present At The 2013 Leerink Swann Global Healthcare Conference

NEW HAVEN, Conn., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Michael Kishbauch, President and Chief Executive Officer of Achillion, will present a corporate update at the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 3:30 p.m. EST at the Waldorf-Astoria Hotel in New York, NY.

The live audio and video broadcast and the subsequent archived webcasts of the Company's presentations will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including the hepatitis C virus (HCV) and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
CONTACT: Company Contact:         Glenn Schulman         Achillion Pharmaceuticals, Inc.         Tel. (203) 752-5510         gschulman@achillion.com                  Investors:         Mary Kay Fenton         Achillion Pharmaceuticals, Inc.         Tel. (203) 624-7000         mfenton@achillion.com

If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence